Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Practically Speaking: Dato-DXd - The ABCs of Dato-DXD ADC in 2nd Line and Beyond

  • Broadcast in Medicine
MedOncNow

MedOncNow

×  

Follow This Show

If you liked this show, you should follow MedOncNow.
h:2444437
s:12370041
archived
Play
  • Host

To be added to the distribution list, please email: DDeCastro@southlakeregional.org

In this episode of the MedOncNow, Dr. Quincy Chu discuss the incorporation of DATO-DXD into our management strategy for advanced staged Non-Sq NSCLC.  He also does highlight the potential new biomarker for staining TROP-2.  This is timely given that we do have access to DATO-DXD via a company sponsored SAP program.

Key Opinion Leader: 

Dr. Quincy Chu MD FRCPC
Medical Oncologist
Associate Professor
Cross Cancer Institute/University of Alberta
Research Lead in Thoracic Oncology
Co-Lead in Phase 1

Host:
Shaqil Kassam MD. MSc. FRCPC
skassam@southlakeregional.org
Medical Oncologist
Stronach Regional Cancer Centre, Newmarket, Ontario 

Previous episodes: https://www.blogtalkradio.com/medoncnow

X - @medoncnow

 

Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled